Albert David Share Price Outlook: Where Could It Be by 2030?

Albert David share price Rs 693 (10 July 2026). 52W high Rs 954, low Rs 580. Market cap Rs 396 Cr. 2030 scenario range Rs 760 to Rs 1,250.

The Albert David share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 693 on 10 July 2026, within a 52 week range of Rs 580 to Rs 954. This article lays out a scenario based Albert David share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Albert David Company Overview

Albert David is a pharmaceutical company manufacturing formulations and active pharmaceutical ingredients, with a legacy presence in the Indian domestic pharma market. Understanding the business model is the first step in framing any credible Albert David share price forecast, because the durability of earnings ultimately decides where the stock trades.

Where Does Albert David Share Price Stand Today?

The stock currently trades about 27 percent below its 52 week high of Rs 954, which means the market has already tempered some of its optimism. For anyone building a Albert David share price forecast, this correction matters for the Albert David share price forecast starting point, because entry valuations have a large bearing on 3 year returns.

At the current price, Albert David commands a market capitalisation of Rs 396 Cr and trades at a price to earnings multiple of NA. The company generates a return on equity of 0.38% and a return on capital employed of 0.77%, which places it in the category of businesses with a recovering profitability profile. These numbers anchor the Albert David share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

Albert David Share Price Forecast: Key Growth Drivers for the Next 3 Years

Four forces are likely to shape the Albert David share price forecast between now and 2030, and together they explain most of the dispersion in this Albert David share price forecast. Each is discussed below with its likely direction of impact.

Earnings Trajectory and Return Ratios

Stock prices ultimately follow earnings. With a recovering profitability profile at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Albert David share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.

Structural Tailwinds in Indian Pharmaceuticals

The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Albert David, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.

Within the space, investors often benchmark Albert David against peers such as Alembic Pharmaceuticals, Aarey Drugs & Pharmaceuticals and Bajaj Healthcare on growth and valuations before forming a view on the Albert David share price forecast.

Company Specific Catalysts

The bull case for Albert David rests on steady domestic formulation demand and any new product launches in its therapeutic portfolio. If these play out on schedule, the Albert David share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.

Macro Environment and Liquidity

The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Albert David share price forecast, while global risk aversion would do the opposite to the Albert David share price outlook.

Albert David Share Price Forecast 2027, 2028 and 2030: Scenario Analysis

The table below presents a scenario based Albert David share price forecast using compounded annual growth assumptions applied to the current market price of Rs 693. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.

In the base case scenario of this Albert David share price forecast, the 2030 level works out to roughly Rs 980, implying steady compounding from today’s levels. The bull case of Rs 1,250 assumes steady domestic formulation demand and any new product launches in its therapeutic portfolio delivers ahead of expectations, while the bear case of Rs 760 captures a scenario where growth stalls. That is an outcome band of about 10 percent to 80 percent over the period.

Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast

Bull Case vs Bear Case for Albert David Share Price

The Bull Case

The optimistic Albert David share price forecast assumes steady domestic formulation demand and any new product launches in its therapeutic portfolio. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 1,250 by 2030.

The Bear Case

The cautious view centres on the fact that competition from larger branded pharma companies and pricing pressure on legacy products are key risks. If these pressures dominate, the Albert David share price forecast would skew toward the lower band and the stock could stagnate near Rs 760 even by 2030, underperforming broader indices.

Key Risks That Could Change the Albert David Share Price Outlook

• Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Albert David share price forecast.
• Valuation risk: At a PE of NA, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
• Sector risk: Competition from larger branded pharma companies and pricing pressure on legacy products are key risks.
• Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
• Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.

Is Albert David Worth Watching for the Long Term?

For long term investors, the relevant question is not just where the Albert David share price forecast lands in 2030 or what any single Albert David share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around steady domestic formulation demand and any new product launches in its therapeutic portfolio gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.

Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Albert David share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.

Download the Univest iOS App or Univest Android App to track Albert David share price live.

Conclusion

The Albert David share price forecast for the next 3 years spans Rs 760 to Rs 1,250 by 2030 under the scenarios discussed, with a base case near Rs 980. Any credible Albert David share price forecast must be updated as facts change, and the path will be decided by earnings delivery, steady domestic formulation demand and any new product launches in its therapeutic portfolio and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.

What is the Albert David share price forecast for the next 3 years?

Ans. The Albert David share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 760 in the bear case to Rs 1,250 in the bull case, with a base case near Rs 980, depending on earnings delivery and market conditions.

What is the Albert David share price forecast for 2027?

Ans. For 2027, the scenario range works out to Rs 715 to Rs 845, with a base case around Rs 780. This assumes compounding on the current price of Rs 693 and is illustrative, not a guaranteed outcome.

What is the Albert David share price forecast for 2028?

Ans. The 2028 scenario range is Rs 730 to Rs 960, with the base case near Rs 840. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.

What is the current share price of Albert David?

Ans. As of 10 July 2026, Albert David trades at around Rs 693 on the NSE, within a 52 week range of Rs 580 to Rs 954. Prices change continuously during market hours, so check live quotes before acting.

Is Albert David a good stock for the long term?

Ans. Albert David has a credible long term story built on steady domestic formulation demand and any new product launches in its therapeutic portfolio, but it also carries risks since competition from larger branded pharma companies and pricing pressure on legacy products are key risks. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What is the Albert David share price outlook for 2030?

Ans. The Albert David share price outlook for 2030 spans Rs 760 to Rs 1,250 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What are the key risks to the Albert David share price forecast?

Ans. The main risks are execution delays, valuation compression from the current PE of NA, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.